SciFi Advisor
Event-driven, biotech, healthcare, small-cap

Ambit Bridging Multi-Decade Gap In Fight Against AML, Other Disease Targets To Follow

Ambit Biosciences (NASDAQ:AMBI) is looking to make an impact on Acute Myloid Leukemia (AML) using a targeted strategy to replace non-specific, decades old therapies currently in use. Ambit's approach is to develop an orally available kinase inhibitor, quizartinib, which targets the FLT3 protein in cancer cells. FLT3 is a receptor tyrosine kinase important for the development of normal blood progenitor cells, and its overexpression or mutation has been linked with hematologic malignancies. In fact, 30-35% of AML patients express a specific mutant form of the protein called FLT3-ITD, while another 20% of patients have high levels of FLT3, making the protein an attractive target.

Investors are likely aware of the success that targeted treatments have, and need look...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details